Identifying Potential Drug Targets and Biomarkers for KCNN2 Dysfunction

Target Name: KCNN2

NCBI ID: G3781

KCNN2

Other Name(s): potassium calcium-activated channel subfamily N member 2 | NEDMAB | KCNN2_HUMAN | apamin-sensitive small-conductance Ca2+-activated potassium channel | SKCa 2 | hSK2 | Small conductance calcium-activated potassium channel protein 2 isoform X1 | KCNN2 variant X1 | Potassium calcium-activated channel subfamily N member 2, transcript variant 1 | SK2 | Potassium calcium-activated channel subfamily N member 2, transcript variant X1 | potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 2 | Small conductance calcium-activated potassium channel protein 2 isoform a | potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | DYT34 | KCNN2 variant 1 | KCa2.2 | SKCa2 | Small conductance calcium-activated potassium channel protein 2 | Small conductance calcium-activated potassium channel protein 2 (isoform X1) | SKCA2 | small conductance calcium-activated potassium channel 2

Identifying Potential Drug Targets and Biomarkers for KCNN2 Dysfunction

KCNN2, a member of the potassium calcium-activated channel subfamily N, has been identified as a potential drug target or biomarker for various neurological and cardiovascular disorders. This channel is involved in the regulation of neuronal excitability and has been implicated in a number of neurological and cardiovascular functions, including muscle contractions, heart rhythm, and blood pressure.

Diseases associated with KCNN2 dysfunction

KCNN2 dysfunction has been implicated in a number of neurological and cardiovascular disorders, including epilepsy, bipolar disorder, Alzheimer's disease, and sudden cardiac death. In epilepsy, KCNN2 dysfunction has been linked to the regulation of neuronal excitability and has been shown to contribute to the pathophysiology of epilepsy. In bipolar disorder, KCNN2 dysfunction has been linked to the regulation of neurotransmitter release and has been shown to play a role in the development and treatment of this disorder. In Alzheimer's disease, KCNN2 dysfunction has been linked to the regulation of neurotransmitter release and has been shown to contribute to the development and progression of this disease. In sudden cardiac death, KCNN2 dysfunction has been linked to the regulation of heart rhythm and has been shown to play a role in the etiology of this disease.

KCNN2 as a drug target

KCNN2 has been identified as a potential drug target for a number of reasons. Firstly, KCNN2 is a voltage-dependent channel that is involved in the regulation of neuronal excitability, making it a potential target for drugs that can modulate voltage-dependent neurotransmitter release. Secondly, KCNN2 is a member of the potassium calcium-activated channel subfamily N, which is known for its role in the regulation of neuronal excitability and has been implicated in a number of neurological and cardiovascular functions. This suggests that drugs that can modulate voltage-dependent neurotransmitter release by targeting this channel may have therapeutic benefits in a number of neurological and cardiovascular disorders.

KCNN2 as a biomarker

In addition to its potential as a drug target, KCNN2 has also been identified as a potential biomarker for a number of neurological and cardiovascular disorders. For example, KCNN2 dysfunction has been shown to be involved in the regulation of neuronal excitability and has been linked to the development and progression of a number of neurological disorders, including epilepsy, bipolar disorder, and Alzheimer's disease. This suggests that drugs that can modulate voltage-dependent neurotransmitter release by targeting this channel may be useful in the treatment of these disorders. Additionally, KCNN2 dysfunction has been shown to be involved in the regulation of heart rhythm and has been linked to the development and progression of sudden cardiac death. This suggests that drugs that can modulate voltage-dependent neurotransmitter release by targeting this channel may also be useful in the treatment of sudden cardiac death.

Conclusion

KCNN2, a member of the potassium calcium-activated channel subfamily N, has been identified as a potential drug target and biomarker for a number of neurological and cardiovascular disorders. Its involvement in the regulation of neuronal excitability and its implication in the development and progression of a number of disorders makes it a promising target for the development of new therapeutic drugs. Further research is needed to fully understand the role of KCNN2 in the regulation of neuronal excitability and to determine the efficacy and safety of drugs that can modulate voltage-dependent neurotransmitter release by targeting this channel.

Protein Name: Potassium Calcium-activated Channel Subfamily N Member 2

Functions: Forms a voltage-independent potassium channel activated by intracellular calcium (PubMed:10991935, PubMed:9287325, PubMed:33242881). Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization

The "KCNN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets